Share this page

 XOZYRLI — 2361537

Toolbar

Toolbar

Details

Third-party disclaimer

Share this page

No endorsement of any products or services is expressed or implied.

Third-party disclaimer

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Application number

2361537

Type(s)

Standard Characters

Category

Trademark

CIPO Status

ADVERTISED

TM5 status

LIVE/APPLICATION/ Published for Opposition
A pending trademark application has been examined by the Office and has been published in a way that provides an opportunity for the public to oppose its registration.

Filed

2024-11-12

Applicant

Teva Pharmaceutical Industries Ltd.
124 Dvora HaNevi'a St.
Tel Aviv, 6944020
ISRAEL

Agent

OSLER, HOSKIN & HARCOURT LLP
Suite 320, World Exchange Plaza
100 Queen Street
Ottawa,
ONTARIO K1P1J9

Documents

View documents

Index headings

  • XOZYRLI

Goods (Nice class & Statement)

5
(1) Pharmaceutical preparations for the prevention and treatment of autoimmune diseases and disorders, blood diseases and disorders, cardiovascular diseases and disorders, digestive diseases and disorders, immunological diseases and disorders, dermatological diseases and disorders, musculoskeletal diseases and disorders, central and peripheral nervous system diseases and disorders, renal diseases and disorders, respiratory diseases and disorders, and urinary diseases and disorders, pharmaceutical preparations for use in the treatment of cancer, drug dependence, fertility disorders, hormone replacement, menopause, ophthalmic disorders and diseases, and pain; pharmaceutical preparations for use in smoking cessation; contraceptive preparations; pharmaceutical preparations for the treatment of asthma, chronic rhinosinusitis, chronic spontaneous urticaria, and food allergies; cardiovascular pharmaceuticals; pharmaceutical preparations for the prevention and treatment of endocrine diseases and disorders, namely, growth and thyroid disorders; pharmaceutical preparations for human use in the field of metabolic disorders, namely, diabetes, obesity, hyperlipidemia, insulin resistance, metabolic syndrome; pharmaceutical preparations for use in urology; pharmaceutical preparations for the treatment of infectious diseases, namely, respiratory infections, eye infections; pharmaceutical preparations for the treatment of inflammation and inflammatory diseases, namely, inflammatory bowel diseases, inflammatory connective tissue diseases, inflammatory pelvic diseases; pharmaceutical preparations for the treatment of psychological disorders, namely, mood disorders, anxiety disorders, cognitive disorders, schizophrenia and bipolar disorders, and psychoses.

Action History

Actions
Action Action date Due date Comments
Filed 2024-11-12
Created 2024-11-12
Formalized 2024-11-12
Pre-Assessment Letter Sent 2024-11-28 Goods or Services Not Acceptable
Search Recorded 2025-09-02
Examiner's First Report 2025-09-02 2026-03-02
Approved 2026-06-10 APPROVED BY PROGRAM EX200M1
Approval Notice Sent 2026-06-10 APPROVED BY PROGRAM EX200M1
Advertised 2026-08-26 Vol.73 Issue 3748
Report a problem on this page
Date modified: